Savara (NASDAQ:SVRA) released its earnings results on Wednesday, March 14th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02, Bloomberg Earnings reports.
NASDAQ SVRA traded down $0.20 during trading hours on Friday, reaching $8.61. The stock had a trading volume of 87,850 shares, compared to its average volume of 178,009. The firm has a market cap of $269.56, a P/E ratio of -4.89 and a beta of 0.04. Savara has a 52-week low of $4.60 and a 52-week high of $17.19. The company has a quick ratio of 16.28, a current ratio of 16.28 and a debt-to-equity ratio of 0.13.
SVRA has been the subject of several recent analyst reports. Ladenburg Thalmann started coverage on Savara in a report on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective for the company. BidaskClub lowered Savara from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 9th. ValuEngine upgraded Savara from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. Finally, Canaccord Genuity set a $25.00 target price on Savara and gave the company a “buy” rating in a research note on Friday, February 16th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Savara presently has an average rating of “Hold” and an average price target of $23.58.
In related news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $12.85, for a total value of $321,250.00. Following the completion of the transaction, the insider now directly owns 219,216 shares of the company’s stock, valued at approximately $2,816,925.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Yuri Pikover acquired 3,734 shares of Savara stock in a transaction that occurred on Thursday, March 29th. The stock was purchased at an average cost of $9.00 per share, with a total value of $33,606.00. Following the completion of the purchase, the director now owns 153,734 shares in the company, valued at approximately $1,383,606. The disclosure for this purchase can be found here. Insiders own 6.93% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Savara (SVRA) Issues Quarterly Earnings Results” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2018/04/07/savara-svra-issues-quarterly-earnings-results-beats-expectations-by-0-02-eps.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.